Biocon Share Price

Biocon

CMP as on 24-Jan-22 12:06

₹ 375.55
-1.55 -0.41%

Open

₹ 377.10

Turnover (lac)

₹ 7,485

Prev. Close

₹ 377.10

Day's Vol (shares)

₹ 19,93,165

Day's Range (₹)

₹ 373.05
₹ 379.85

CMP as on24-Jan-22 12:06

₹ 375.30
-1.3 -0.35%

Open

₹ 378.40

Turnover (lac)

₹ 402

Prev. Close

₹ 376.60

Day's Vol (shares)

₹ 81,513

Day's Range

₹ 373.15
₹ 379.50

CMP as on 24-Jan-22 12:06

₹ 376.15
-0.5 -0.13%

Open

₹ 376.70

Open Interest(Contracts)

₹ 1,55,98,600

VWAP

₹ 376.36

Day's Vol (shares)

₹ 68,12,600

Day's Range (Ex.Dt. 27 Jan 2022)

₹ 373.00
₹ 380.55

Corporate Action

Go
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 03-Jan-2022 - -
BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/01/2022 inter alia to consider and approve Pursuant to Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Thursday January 20 2022 inter alia to approve and take on record the un-audited standalone and consolidated financial results for the quarter and nine months ended December 31 2021 amongst other routine matters. The trading window for dealing in securities of the Company for all insiders as defined under the Code of Conduct for Prevention of Insider Trading (the Code) of the Company has been closed from January 1 2022 to January 22 2022 (both days inclusive) in compliance with the provisions of the Code of the Company read with SEBI (Prohibition of Insider Trading) Regulations.
Board Meeting - 03-Jan-2022 - -
This is in continuation to our intimation dated September 16, 2021, with regard to merger of Covidshield Technologies Private Limited (CTPL or the Transferor Company), a wholly-owned subsidiary of Serum Institute Life Sciences Private Limited (SILS), with, and into Biocon Biologics Limited (BBL or the Transferee Company), a material subsidiary of Biocon Limited (the Company). We would like to inform that the Board of Directors of BBL at its meeting held today i.e., January 3, 2022, has approved the scheme of Merger by Absorption (Scheme) pursuant to Section 230 to 232 of the Companies Act, 2013 for the said merger as mentioned above. The scheme is subject to the requisite statutory approvals including approval of the National Company Law Tribunal (NCLT) and/ or such other competent authorities (including the Competition Commission of India), and the shareholders and creditors of the Transferor Company and the Transferee Company.
Board Meeting - 05-Oct-2021 - -
Quarterly Results Pursuant to Regulation 30 and 33 of SEBI (Listing Obligation and Disclosure Requirements) 2015, we wish to inform you that the Board of Directors at its meeting held today, has considered and approved the un-audited financial results (standalone and consolidated) as per Indian Accounting Standard (Ind-AS) along with Limited Review Report for the quarter and half year ended September 30, 2021. A copy of the un-audited financial results along with the Limited Review Report is enclosed herewith. (As per BSE Announcement Dated on 21/10/2021)
Board Meeting - 06-Jul-2021 - -
BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/07/2021 ,inter alia, to consider and approve Pursuant to Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Thursday, July 22, 2021, inter alia, to approve and take on record the un-audited standalone and consolidated financial results for the quarter ended June 30, 2021, amongst other routine matters. The trading window for dealing in securities of the Company for all insiders, as defined under the Code of Conduct for Prevention of Insider Trading (the Code) of the Company, has been closed from July 1, 2021 to July 24, 2021 (both days inclusive) in compliance with the provisions of the Code of the Company read with SEBI (Prohibition of Insider Trading) Regulations. The above mentioned information will also be available on website of the Company at www.biocon.com. Financial Results for the quarter ended June 30, 2021 (As Per BSE Announcement dated on 22.07.2021)
Board Meeting - 12-Apr-2021 - -
BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/04/2021 ,inter alia, to consider and approve approve and take on record the audited standalone and consolidated financial results for the quarter and year ended March 31, 2021 and to consider the recommendation of final dividend, if any, amongst other routine matters. Approved audited financial results (consolidated and standalone) as per Indian Accounting Standard (Ind-AS) along with Auditors Report for the quarter and year ended March 31, 2021. A copy of the audited financial results along with the Auditors Report and a declaration under Regulation 33(3)(d) of SEBI Listing Regulations are enclosed herewith. (As Per BSE Announcement dated on 28.04.2021) Allotment of equity shares to Biocon India Limited Employee Welfare Trust under Biocon Restricted Stock Unit Long Term Incentive Plan FY 2020-24. Update on declaration of dividend for FY21 (AS Per BSE Announcement Dated on 29.04.2021)
Open ZERO Brokerage Demat Account Open ZERO Brokerage Demat Account

  • 0

    Delivery Brokerage for Lifetime

  • 20

    Per order for Intraday, F&O, Currency & Commodity